Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2707]

Circulating tumour cells may predict late recurrence in HR-positive breast...

Dr Joseph Sparano - Albert Einstein Cancer Center, New York, USA

Circulating tumour cells may predict late recurrence in HR-positive breast cancer patients ( Dr Joseph Sparano - Albert Einstein Cancer Center, New York, USA )

Postmenopausal women who lose weight may have reduced breast cancer risk

Prof Rowan Chlebowski - City of Hope, Duarte, USA

Postmenopausal women who lose weight may have reduced breast cancer risk ( Prof Rowan Chlebowski - City of Hope, Duarte, USA )

Talazoparib vs physicians choice for patients with mBRCA1 breast cancer

Prof Jennifer Litton - MD Anderson Cancer Center, Houston, USA

Talazoparib vs physicians choice for patients with mBRCA1 breast cancer ( Prof Jennifer Litton - MD Anderson Cancer Center, Houston, USA )

CDK 4/6 inhibitors for older women with HR-positive breast cancer

Harpreet Singh - FDA, USA

CDK 4/6 inhibitors for older women with HR-positive breast cancer ( Harpreet Singh - FDA, USA )

Reducing risk of breast cancer recurrence and death with increased dose density

Prof Richard Gray - University of Oxford, Oxford, UK

Reducing risk of breast cancer recurrence and death with increased dose density ( Prof Richard Gray - University of Oxford, Oxford, UK )

Breast cancer therapy resistance mediated by FGFR amplification

Dr Luigi Formisano - Vanderbilt University Medical Center, Nashville, USA

Breast cancer therapy resistance mediated by FGFR amplification ( Dr Luigi Formisano - Vanderbilt University Medical Center, Nashville, USA )

The significance of CEACAM 5 in metastases of triple negative breast cancer

Emily Powell - MD Anderson Cancer Center, Houston, USA

The significance of CEACAM 5 in metastases of triple negative breast cancer ( Emily Powell - MD Anderson Cancer Center, Houston, USA )

Results of the MONALEESA 7 trial

Prof Debu Tripathy - MD Anderson Cancer Center, Houston, USA

Results of the MONALEESA 7 trial ( Prof Debu Tripathy - MD Anderson Cancer Center, Houston, USA )

The REACT trial: Celecoxib vs placebo for primary breast cancer

Prof Charles Coombes - Imperial College School of Medicine, London, UK

The REACT trial: Celecoxib vs placebo for primary breast cancer ( Prof Charles Coombes - Imperial College School of Medicine, London, UK )

Rationale and recruitment in the PARTNER trial

Dr Jean Abraham - University of Cambridge, Cambridge, UK

Rationale and recruitment in the PARTNER trial ( Dr Jean Abraham - University of Cambridge, Cambridge, UK )

The role of axiliary node dissection in modern breast cancer surgery

Dr Viviana Galimberti - European Institute of Oncology, Milan, Italy

The role of axiliary node dissection in modern breast cancer surgery ( Dr Viviana Galimberti - European Institute of Oncology, Milan, Italy )

Anastrozole duration for post-menopausal breast cancer patients after 5 years...

Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria

Anastrozole duration for post-menopausal breast cancer patients after 5 years of endocrine therapy ( Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria )

More from ecancer